Join to View Full Profile
3855 Health Sciences Dr # 987La Jolla, CA 92093
Phone+1 858-822-5182
Fax+1 858-822-6186
Dr. Gold is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
University of Pennsylvania Health SystemResidency, Internal Medicine, 2005 - 2008
Washington University in St. Louis School of MedicineClass of 2005
Certifications & Licensure
CA State Medical License 2015 - 2025
TX State Medical License 2008 - 2024
PA State Medical License 2005 - 2008
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin Start of enrollment: 2011 Feb 01
- Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2018 Jun 06
Publications & Presentations
PubMed
- 8 citationsSpatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort.William N William Jr, Jianjun Zhang, Xin Zhao, Edwin R Parra, Naohiro Uraoka
Cancer. 2023-03-01 - 10 citationsA phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.Michael J Dennis, Assuntina G Sacco, Yuchen Qi, Julie Bykowski, Emily Pittman
Oral Oncology. 2022-12-01 - 13 citationsClinicopathologic and molecular characteristics of-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy.Li Yu, Lyudmila Bazhenova, Kathryn Gold, Lisa Tran, Van Hilburn
Translational Lung Cancer Research. 2022-03-01
Press Mentions
COVID-19 Pandemic Is Driving up Rate of Late-Stage Cancer Diagnoses, UCSD Researchers SayFebruary 17th, 2022- COVID Pandemic Driving up Late-Stage Cancer Rates, UCSD FindsFebruary 15th, 2022
- Increase in Late-Stage Cancer Diagnoses After PandemicFebruary 15th, 2022
Grant Support
- Therapeutic Targeting of Macrophage PI3Kgamma in HNSCCUNIVERSITY OF CALIFORNIA, SAN DIEGO2018–2028
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
